OXpeptides

Compound guide · 10 min read

TB-500 (Thymosin Beta-4): Research Guide, Mechanism & Dosing

By Marcus Reyes, Research analyst — metabolic & regenerative peptides. Scientifically reviewed by Dr. Aaron Vogt, PhD. Updated 2026-06-01.

TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4, a 43-amino-acid protein present in almost every human cell. In research models it regulates actin and promotes cell migration, angiogenesis and tissue repair. With a molecular mass near 4,963 Da, it is sold as a research reagent only — not for human or veterinary use.

What is TB-500?

TB-500 is a synthetic research peptide built around the active region of Thymosin Beta-4 (often written Tβ4), a small protein of 43 amino acids that occurs in nearly every cell of the human body. Tβ4 is the most abundant member of the beta-thymosin family and one of the principal regulators of actin, the structural protein that lets cells change shape and move. TB-500 reproduces the part of that protein responsible for binding actin, which is why researchers treat it as a focused tool rather than the whole, harder-to-handle protein.

Chemically, TB-500 has a molecular mass of about 4,963 Da. That figure is useful when you source material: a mass-spectrometry result on a Certificate of Analysis should match it closely, which is the simplest way to confirm you have the real peptide and not a truncated by-product.

How TB-500 works: actin, migration and repair

The defining activity of TB-500 is actin sequestration. By binding monomeric (G-)actin, it influences how quickly the cytoskeleton assembles and disassembles — and that, in turn, governs how readily cells migrate toward an injury. The literature describes four interlocking roles, all reported in animal and cell-culture models rather than humans.

FunctionMechanismReported relevance
Actin regulationSequesters G-actin, the most abundant cytoskeletal proteinFoundational to cell shape and movement
Cell migrationModulates actin polymerisation so cells move to damaged zonesFaster repopulation of an injury site
AngiogenesisSupports formation of new blood vesselsImproved perfusion of healing tissue
Inflammation controlDocumented anti-inflammatory and immunomodulatory effectsA calmer local repair environment

What the TB-500 research evidence shows

Unlike many research peptides, Thymosin Beta-4 has reached human clinical trials in specific formulations, which gives the underlying biology more weight than animal data alone.

  • Cardiac repair. Bock-Marquette et al. (2004, Nature) reported that Tβ4 improved cardiomyocyte survival and promoted new vessel growth in injured heart tissue — a landmark paper that drew attention to the molecule.
  • Skin and wound healing. Malinda et al. (1999, Journal of Investigative Dermatology) reported accelerated wound closure with increased keratinocyte and endothelial-cell migration.
  • Corneal repair. RGN-259, a Tβ4 eye-drop developed by RegeneRx Biopharmaceuticals, advanced into phase 2/3 clinical trials for dry-eye and corneal wound healing — a rare example of a beta-thymosin reaching late-stage human study.
Note the distinction. Human trials studied specific Thymosin Beta-4 formulations (e.g. RGN-259), not the research-chemical TB-500 fragment sold for laboratory use. The clinical work supports the biology, but TB-500 itself is not an approved drug and carries no human efficacy or safety approval.

TB-500 reconstitution and dosing in research

TB-500 is shipped as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water before use in a model. The concentration is simply mass divided by volume.

  1. Bring the TB-500 vial and bacteriostatic water to room temperature (about 15 minutes).
  2. Swab the rubber stopper of both the peptide vial and the water vial with alcohol.
  3. Draw the chosen volume of bacteriostatic water with a sterile insulin syringe — 2 mL is a common choice.
  4. Angle the needle against the inner glass wall and let the water trickle down; do not spray it onto the lyophilized powder.
  5. Roll the vial gently between your palms until the solution is clear. Never shake.
  6. A 5 mg vial in 2 mL gives 2.5 mg/mL (2,500 µg/mL); the same vial in 1 mL gives 5 mg/mL.
  7. Store the reconstituted solution at 2–8 °C, protected from light, and use within 3–4 weeks.

For dosing, preclinical protocols cluster around 2–10 µg per kg of bodyweight per dose, applied a few times per week — figures drawn from animal models, not human guidance. The full concentration-math walkthrough (how to convert a µg target into a volume to withdraw) is shared with the BPC-157 dosage guide, which uses the same method.

Sourcing TB-500: what to check

Because TB-500 is widely sold, the burden is on the researcher to verify quality. A very low price is usually a signal of poor purity or careless storage rather than a bargain.

  • Purity ≥ 99% by HPLC, with a recent batch COA from a named laboratory such as Janoshik.
  • Mass near 4,963 Da confirmed by mass spectrometry on that COA.
  • White, intact lyophilizate — any yellow or brown tint suggests degradation.
  • Vial sealed under vacuum or inert gas to prevent oxidation, and shipped light-protected.

For the cross-compound view of purity, storage and red flags, see the complete research peptides guide.

TB-500 and BPC-157 in regeneration research

The most studied pairing in this space combines TB-500 with BPC-157. The logic is complementary mechanisms: TB-500 works systemically via actin and cell migration, while BPC-157 acts locally and drives angiogenesis. Our BPC-157 research guide breaks down that compound in full.

Frequently asked questions

What is TB-500?+

TB-500 is a synthetic peptide that reproduces the biologically active region of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein found in nearly all human cells. In research it is studied for its role in actin regulation, cell migration, angiogenesis and tissue repair. It is supplied strictly as a research reagent and is not an approved medicine.

What is the difference between TB-500 and Thymosin Beta-4?+

Thymosin Beta-4 is the full 43-amino-acid protein. TB-500 is a shorter synthetic peptide built around the actin-binding region thought to drive most of the repair-related activity. The two names are often used interchangeably in casual discussion, but they are technically distinct molecules — TB-500 is a focused fragment, not the whole protein.

What dosage of TB-500 is used in research?+

Across preclinical models, TB-500 is typically investigated in the range of roughly 2–10 µg per kg of bodyweight per dose, often a few times per week. These are animal-model figures, not human guidance. For the concentration math and worked examples, see the dosage section and the BPC-157 dosage guide on this site.

How is TB-500 reconstituted and stored?+

Reconstitute the lyophilized powder with bacteriostatic water added slowly down the vial wall, then swirl gently — never shake. A 5 mg vial in 2 mL yields 2.5 mg/mL. Store the sealed powder at -20 °C for long-term stability; the reconstituted solution keeps for about 3–4 weeks at 2–8 °C, protected from light.

Why is TB-500 studied together with BPC-157?+

The TB-500 + BPC-157 pairing is one of the most documented combinations in regeneration research because the mechanisms are complementary: TB-500 acts systemically through actin regulation and cell migration, while BPC-157 acts locally and promotes angiogenesis. Both are research reagents only.

Buy research-grade TB-500, >99% purity

Lyophilized, batch COA on request, plain packaging, tracked worldwide shipping.

View TB-500 vials →

For research use only. Not for human or animal use. Not a drug. The findings summarised above describe published preclinical and clinical research on Thymosin Beta-4 and are not medical advice or a claim of efficacy for TB-500. Citations: Bock-Marquette et al., Nature 2004; Malinda et al., J. Invest. Dermatol. 1999; RegeneRx RGN-259 trials (PubMed).